The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
We grade stocks based on past performance, their future growth potential, intrinsic value, dividend history, and overall financial health.
The chart below shows how we grade SAB Biotherapeutics (SABS) across the board compared to its closest peers.
Benzinga Edge stock rankings give you four critical scores to help you identify the strongest and weakest stocks to buy and sell.
See how SAB Biotherapeutics compares to its peers in these key performance metrics from Benzinga Rankings.
Earnings History (3 years)
It is important to look at a companies earnings history to see not only if they are profitable, but if their earnings are growing.The two main factors that we consider when analyzing past performance is overall return and volatility
Using these two metrics, we can determine if this stock gave its investors enough return for the risk that they took on by owning it. This is measured by the sharpe ratio, which has been used as a primary measure of risk/reward trade-off for almost 60 years.
This ratio can be interpreted as the amount of return an investor has received for the amount of risk that they took on by owning the stock over that timeframe.
SAB Biotherapeutics (SABS) sharpe ratio over the past 5 years is -0.1457 which is considered to be above average compared to the peer average of -0.4593
